Loading
A phase 2 trial of Niraparib in ovarian cancer, run by GlaxoSmithKline, now recruiting.
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study is a phase 2 interventional study registered as NCT04641247 by GlaxoSmithKline, with 37 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-12-28. Interventions recorded: Niraparib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Niraparib, GSK, PARP inhibitors, Ovarian cancer and the tag pipeline.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares PARP inhibitors, Ovarian cancer and the tag pipeline.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares Niraparib, PARP inhibitors and the tag pipeline.
Shares GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/